Dynamic cell reprogramming without gene editing making personalized medicine scalable. We're starting with cancer and soon extending longevity.

CellRep is revolutionizing cell therapy based on our co-founder Dr. Federico Perdomo's groundbreaking discovery that cells are programmable biological supercomputers. While at Institut Pasteur, Dr. Perdomo demonstrated that dysfunctional T cells could be reprogrammed with small molecules to emulate the extraordinary properties of T cells from HIV natural controllers—creating rejuvenated fighters with enhanced survival, polyfunctionality, and metabolic plasticity.
Our AI-powered platform expands on this breakthrough through our integrated In Silico, In Vitro, and In Vivo approach, dynamically reprogramming T cells without genetic modification to address the critical limitations in today's CAR-T therapies: poor efficacy in solid tumors, lengthy manufacturing times, and prohibitive costs.
We've already identified 15+ novel molecular targets and achieved a 2.5x improvement in T cell functionality—47% better than Dr. Perdomo's original breakthrough. Our technology produces more polyfunctional, "younger" T cells with potential to reduce manufacturing time by 45% while improving therapeutic outcomes by 50%.
With strategic partnerships established with major research institutions and engagement from leading pharmaceutical companies, we're transforming the $7B CAR-T market (projected to reach $188B by 2034) while building the definitive bio-compiler for cellular medicine across multiple therapeutic areas.

CellRep

Org chart

Teams

Offices

CellRep

Org chart

Teams

Offices

Related companies